Velpatasvir is an inhibitor of drug transporter breast cancer resistance protein (BCRP). Co-administration of Epclusa with medicinal products that are substrates of these transporters (such as rosuvastatin) may increase the exposure of such medicinal products. Co-administration of Epclusa with rosuvastatin increases the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. Rosuvastatin, at a dose that does not exceed 10 mg, may be administered with Epclusa. Coadministration of rosuvastatin (10 mg single dose) and velpatasvir (100 mg once daily) increased rosuvastatin Cmax and AUC by 160% and 170%. The effect on velpatasvir exposure was not studied but no change is expected. Interaction only studied with velpatasvir, but no effect on sofosbuvir is expected.